Protagonist Therapeutics Inc. (NASDAQ:PTGX) is one of the best mid cap growth stocks to invest in now. Just as June began, ...

Protagonist Therapeutics' partners ought to secure two approvals for blockbuster drugs within the next year. Click here to ...

Silence Therapeutics presents additional data from phase 1 study of divesiran as potential first-in-class siRNA treatment for polycythemia vera: London Monday, June 16, 2025, 18:0 ...

Early results from the phase 1 SANRECO trial suggest that divesiran is safe and well tolerated, and may reduce the need for phlebotomy in patients with polycythemia vera by increasing hepcidin levels ...

Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with polycythemia vera.

Heart muscle cells do something similar, issuing electrical “heave-ho” signals that make the organ beat. Skin and other epithelial cells, however, were thought to be silent; they form barrier ...

Seabream Hepcidin 作为铁代谢调节因子，作用机理与哺乳动物 Hepcidin 类似： 调控铁外流：通过结合细胞膜上的铁转运蛋白 Ferroportin（Fpn），促使其内化和降解，抑制细胞内铁向外释放，从而降低血清铁浓度。

The VERIFY trial explores rusfertide to manage polycythemia vera without causing iron deficiency symptoms, Dr. Aaron Gerds ...

For patients with a rare type of blood cancer, treatment might finally be coming out of the Dark Ages. People with the chronic condition polycythemia vera make too many red blood cells, thickening ...

Claudin-18 isoform 2 (CLDN18.2) has emerged as a promising therapeutic target in gastric or gastro-oesophageal junction cancer. Satricabtagene autoleucel (satri-cel; also known as CT041), an ...

哺乳动物 Hepcidin 通过结合铁转运蛋白（Ferroportin）调控铁稳态，但鱼类 Hepcidin 此功能尚未完全阐明。 研究历程. 发现： 1994 年首次从人尿中分离出 Hepcidin，随后在鱼类（如虹鳟、鲈鱼）中发现同源物，2000 年代初确认其抗菌活性。 鱼类研究： ...

Background: PV is characterized by red blood cell overproduction. Rusfertide is a subcutaneous (SC), self-injected, first-in-class peptide hepcidin mimetic that decreases erythrocytosis. VERIFY ...